Estimates place the size of the global monoclonal antibodies market at US$ 186 billion in 2021, with a compound annual growth rate (CAGR) of 12% from 2022 to 2032. The market for monoclonal antibodies (mAbs) is expected to be driven primarily by the growing demand for biologics due to the increasing prevalence of chronic diseases including cancer, cardiovascular disorders, and others. Similar to this, growing uses of monoclonal antibodies (mAbs) for targeted therapeutics and growing patient and physician knowledge of these therapies are anticipated to have a substantial impact on market expansion.
Compared to chimeric or humanised mAbs, human mAbs are less immunogenic and provide effective regulation of effector activities. Phage display and hybridoma technologies in transgenic mice can be used to manufacture such antibodies. Therefore, it is projected that the manufacture of fully human mAbs will gain popularity soon because to recent scientific advancements in genetic engineering.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-15756
North America recorded the largest market share of 46.2% in 2021 due to the presence of a highly developed healthcare infrastructure, high patient awareness, and growth in cancer research prospects, among other factors. Moreover, increasing government expenditure for cancer research and the presence of key players such as Pfizer Inc., Amgen, Inc., and Merck & Co., among others, are expected to boost the market growth.
Rising healthcare expenditure across the world, increasing patient awareness levels, and availability of advanced hospital infrastructure in developed countries are factors expected to result in the dominance of the segment during the forecast period.
Key Takeaways:
- In 2022, the global monoclonal antibodies market size was valued at USD 186 billion in 2021.
- The market is projected to increase at a CAGR of 12% during the forecast period between 2022 and 2032, reaching a total of US$ 647.01 Billion in 2032
- The human source type held the largest share and accounted for 54.07% of the market value in 2021.
- The North American market for monoclonal antibodies expanded with a market share of 46.2% in 2022.
- Asia Pacific is projected to exhibit the fastest growth rate in the forecast period.
“Applications of mAbs for the treatment of autoimmune diseases are projected to grow at a lucrative rate due to the increasing prevalence of autoimmune conditions such as rheumatoid arthritis.” comments a Future Market Insights analyst.
Elevate Strategy: Tap into Analyst Expertise Now:
https://www.futuremarketinsights.com/ask-question/rep-gb-15756
Competitive Landscape
The market is expected to become more competitive in the near future, as many companies focus their efforts on research and the creation of innovative diagnostic techniques through product line expansions, acquisitions, and mergers. Key players in the Monoclonal Antibodies market areNovartis AG; Pfizer Inc; GlaxoSmithKline plc; Amgen Inc.; Merck & Co., Inc.; Daiichi Sankyo Company, Limited; Abbott Laboratories; AstraZeneca plc; Eli Lilly And Company; Johnson & Johnson Services, Inc. and many more.
- In November 2021, Bristol-Myers Squibb Company received the U.S. Food and Drug Administration approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) combined with limited chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer. Patients with squamous or non-squamous illness, independent of PD-L1 expression, are eligible for the treatment. 1 The FDA’s Real-Time Oncology Examine (RTOR) pilot programme was used to review this application, which aims to ensure that safe and effective medicines are offered to patients as soon as feasible.
- In March 2022, Sanofi S.A. and Blackstone Life Sciences entered a collaboration for accelerating the development of a subcutaneous formulation of Sarclisa mAb for the treatment of patients with multiple myeloma.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global monoclonal antibodies market, presenting historical analysis from 2016 to 2021 and forecast statistics for the period of 2022 to 2032.
The study reveals essential insights on the basis of test type (tumor biomarkers tests, imaging, biopsy, liquid biopsy, immunohistochemistry, in situ hybridization), by indication (breast cancer, lung cancer, colorectal cancer, melanoma, blood cancer, prostate cancer, ovarian cancer, stomach cancer, liver cancer and others) and by end-user (hospital associated labs, independent, diagnostic laboratories, diagnostic imaging centers, cancer research institutes and others) and regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).
Key Segments Profiled in the Monoclonal Antibodies Market Industry Survey
Monoclonal Antibodies Market by Production Type:
- In Vivo
- In Vitro
Monoclonal Antibodies Market by Source Type:
- Murine
- Chimeric
- Humanized
- Human
Monoclonal Antibodies Market by End User:
- Hospitals
- Specialty Centers
- Others
Monoclonal Antibodies Market by Application:
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Neurological Diseases
- Others
Monoclonal Antibodies Market by Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Unleash Potential: Craft Your Customized Report Now:
https://www.futuremarketinsights.com/customization-available/rep-gb-15756
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
